Pfizer & MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid

Tiered Pricing To Allow Equitable Access

An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it’s necessarily a good deal for lower-income countries.

License deals can help improve access to COVID-19 products across the world • Source: Alamy

In a move intended to maximize access to what has been described as a potential “game-changer” COVID-19 therapy, Pfizer Inc. has signed a deal with the Medicines Patent Pool for the voluntary licensing of its candidate oral antiviral, Paxlovid (PF-007321332, in combination with ritonavir).

The agreement covers 95 countries representing about 53% of the world’s population, including all low- and lower-middle-income countries as well...